Clinical data from the light-up study presented at the international congress of endocrinology suggests new gelesis oral hydrogel may improve insulin sensitivity and favorably impact metabolic syndrome

Boston--(business wire)--gelesis holdings inc. (nyse: gls) (“gelesis” or the “company”) the maker of plenity for weight management, today released a poster presentation at the international congress of endocrinology in singapore. the light-up study evaluated the safety and efficacy of gs200, an investigational oral hydrogel, which was designed to emulate the properties of ingested raw vegetables, with slightly different mechanical properties compared to plenity (gs100). the light-up study was c
GLS Ratings Summary
GLS Quant Ranking